New Path Diagnostics LLC

New Path Diagnostics LLC was paid $5.78M by Medicaid between Jan 2018 and Nov 2024, across 14 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 35% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#24 of 116

Median peer was paid$618K

This provider vs. median9.3×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	8,386	$456K
2019	6,263	$343K
2020	14,953	$912K
2021	50,755	$2.12M
2022	15,457	$755K
2023	8,700	$599K
2024incomplete	8,929	$588K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	35%	30,367	26,814	$2.00M
88305	Level IV - Surgical pathology, gross and microscopic examination	31%	26,498	24,555	$1.82M
88312		9.9%	11,077	11,049	$571K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	8.5%	23,456	20,826	$490K
88313		6.1%	7,854	7,841	$353K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	3.1%	2,082	2,006	$177K
88121		2.8%	968	965	$163K
88342		2.3%	4,937	4,922	$131K
88112		<1%	2,028	1,975	$42K
88341		<1%	301	300	$22K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	3,679	3,355	$10K
86328		<1%	39	38	$1K

2 more codes

99080		0%	94	$0.00
99000		0%	63	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTAN, JIANYOU (PRESIDENT)